Developmental Research (Ingle)

梅奥诊所乳腺癌孢子将最大限度地增加发展研究计划中创新和高质量的项目数量。该计划的目标是支持创新的、具有科学价值的研究项目，这些项目的研究结果可以转化为临床上重要的应用，这些应用将影响乳腺癌的诊断和治疗，以减少这种疾病的负担和死亡率。该计划将：1)鼓励和征集创新的转化性实验室、人群和临床研究建议；2)鼓励和支持乳腺癌转化性研究中的跨学科合作；3)产生可在可能影响乳腺癌的更大规模研究项目或临床试验中检验的新假设。这种支持的提供刺激了研究界的创造力，是鼓励基础科学家和翻译研究人员互动的工具，并提供了一个机会，通过在发现和/或出现的机会基础上寻求新的线索来扩大孢子的研究范围。发展研究计划将为六个项目的每个项目提供为期一年的50,000美元(孢子基金25,000美元，梅奥诊所癌症中心25,000美元)。将有可能在证明取得足够进展的基础上再提供第二年的支助。在梅奥诊所乳腺癌孢子的初始赠款期间，设立了一个程序，每年征集申请，并利用内部科学咨询委员会和其他有经验的调查人员的专门知识进行正式同行审查。由于这一进程的成功，它将继续下去。选择资助项目的标准是基于科学价值、原创性、申请者的资格和翻译潜力。预期对发展研究项目的支助将产生数据，这些数据将作为其他孢子赞助项目或通过同行审查的外部赠款支助提供支助的基础。孢子领导的意图是鼓励和帮助研究人员利用这些项目产生的数据来建立乳腺癌的临床前或临床试验。此外，孢子领导层将与调查人员合作，确保独立的R01级资金。在这次孢子更新的四个完整项目中，有两个项目的共同负责人是发展研究计划获得者，这表明发展研究计划在前一个资助期在这方面取得了成功。

The Mayo Clinic Breast Cancer SPORE will maximize the number of innovative and high-quality projects in the Developmental Research Program. The goal of this program is to support innovative, scientifically meritorious research projects from which findings can be translated into clinically important applications that will impact diagnosis and management of breast cancer in order to decrease the burden and mortality from this disease. This program will: 1) encourage and solicit innovative translational laboratory, population, and clinical study proposals; 2) encourage and support interdisciplinary collaboration in translational research in breast cancer; and 3) generate new hypotheses that can be tested in larger-scale research projects or clinical trials that can impact breast cancer. The availability of this support provides a stimulus for creativity in the research community, a vehicle for encouraging the interaction of basic scientists and translational investigators, and an opportunity for expanding the research spectrum of the SPORE by pursuing new leads based on discoveries and/or opportunities that arise. The Developmental Research Program will provide $50,000 for one year ($25,000 from SPORE funds and a matching $25,000 from Mayo Clinic Cancer Center) to each of six projects. There will be the possibility of a second year of support based on demonstration of sufficient progress. A process was established during the initial grant for the Mayo Clinic Breast Cancer SPORE involving a call for applications on an annual basis and a formal peer review utilizing the expertise of the Internal Scientific Advisory Committee and other experienced investigators. Because of the success of this process, it will be continued. Criteria for selection of projects for funding are based upon scientific merit, originality, qualifications of the applicant, and translational potential. It is expected that support of developmental research projects will result in generation of data that will serve as the basis for additional SPORE-sponsored projects or support through peer reviewed external grant support. It is the intent of the SPORE leadership to encourage and help the investigators to use the data generated by these projects to establish preclinical or clinical trials in breast cancer. In addition the SPORE leadership will work with the investigators to secure independent R01-level funding. Two of the four full Projects in this SPORE renewal have a co-leader who was a Developmental Research Program awardee, which indicates that the Developmental Research Program has been successful in this regard during the previous funding period.